Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis

详细信息    查看全文

• 作者：Lixin Wang (1)
  Jinsong Cheng (2)
  Jinyu Gao (3)
  Jipeng Wang (1)
  Xiaoning Liu (4)
  Liwen Xiong (5)
  
• 关键词：NBS1 ; Lung cancer ; Polymorphism ; Meta ; analysis
• 刊名：Molecular Biology Reports
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：40
• 期：3
• 页码：2711-2715
• 全文大小：206KB
• 参考文献：1. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-380 CrossRef
  2. El-Basmy A, Al-Mohannadi S, Al-Awadi A (2012) Some epidemiological measures of cancer in kuwait: national cancer registry data from 2000-009. Asian Pac J Cancer Prev 13:3113-118
  3. De Ruysscher D, Faivre-Finn C, Nestle U et al (2010) European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 28:5301-310 CrossRef
  4. Fidias P, Novello S (2010) Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:5116-123 CrossRef
  5. Goldstraw P, Ball D, Jett JR et al (2011) Non-small-cell lung cancer. Lancet 378:1727-740 CrossRef
  6. Pennathur A, Luketich JD (2009) Multimodal treatment with surgical resection for stage IIIB non-small-cell lung cancer. Lancet Oncol 10:742-43 CrossRef
  7. van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378:1741-755 CrossRef
  8. Brennan P, Hainaut P, Boffetta P (2011) Genetics of lung-cancer susceptibility. Lancet Oncol 12:399-08 CrossRef
  9. Dong LM, Potter JD, White E et al (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299:2423-436 CrossRef
  10. Tseng SF, Chang CY, Wu KJ et al (2005) Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1. J Biol Chem 280:39594-9600 CrossRef
  11. Falck J, Forment JV, Coates J et al (2012) CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination. EMBO Rep 13:561-68 CrossRef
  12. Yanagihara H, Kobayashi J, Tateishi S et al (2011) NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol eta-dependent translesion DNA synthesis. Mol Cell 43:788-97 CrossRef
  13. Foster SS, De S, Johnson LK et al (2012) Cell cycle- and DNA repair pathway-specific effects of apoptosis on tumor suppression. Proc Natl Acad Sci USA 109:9953-958 CrossRef
  14. Wu J, Zhang X, Zhang L et al (2012) Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol Cell 46:351-61 CrossRef
  15. Hebbring SJ, Fredriksson H, White KA et al (2006) Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 15:935-38 CrossRef
  16. Lu M, Lu J, Yang X et al (2009) Association between the NBS1 E185Q polymorphism and cancer risk: a meta-analysis. BMC Cancer 9:124 CrossRef
  17. Park SL, Bastani D, Goldstein BY et al (2010) Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis 31:1264-271 CrossRef
  18. Zhao JW, Ling XX, Yang L et al (2011) Association of polymorphism 8360G>C in NBS1 gene and the risk of lung cancer in southern Chinese population. Acad J Guangzhou Med Coll 39:5-
  19. Zienolddiny S, Campa D, Lind H et al (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27:560-67 CrossRef
  20. Lan Q, Shen M, Berndt SI et al (2005) Smoky coal exposure, NBS1 polymorphisms, p53 protein accumulation, and lung cancer risk in Xuan Wei, China. Lung Cancer 49:317-23 CrossRef
  21. Ryk C, Kumar R, Thirumaran RK et al (2006) Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer 54:285-92 CrossRef
  22. Fan LH, Chen JL, Cai L (2010) Study on the association between DNA double-strand break repair gene NBS1 polymorphisms and susceptibility on lung cancer. Zhonghua Liu Xing Bing Xue Za Zhi 31:213-17
  23. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-60 CrossRef
  24. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-48
  25. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-88 CrossRef
  26. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-101 CrossRef
  27. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-34 CrossRef
  28. Liang G, Lin DX (2004) Polymorphisms in DNA repair genes and susceptibility to lung cancer. Chinese Peking Union Medical University Doctoral Dissertation 2004
  29. Wang Z, Cui D, Lu W (2010) NBS1 8360G>C polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 123:557-61 CrossRef
  30. Hou YY, Toh MT, Wang X (2012) NBS1 deficiency promotes genome instability by affecting DNA damage signaling pathway and impairing telomere integrity. Cell Biochem Funct 30:233-42 CrossRef
  31. Xu JL, Hu LM, Huang MD et al (2012) Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Asian Pac J Cancer Prev 13:851-56 CrossRef
  32. Hsu DS, Chang SY, Liu CJ et al (2010) Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. Cancer Sci 101:1029-037 CrossRef
  33. Ehlers JP, Harbour JW (2005) NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res 11:1849-853 CrossRef
  34. Yang MH, Chiang WC, Chou TY et al (2006) Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 12:507-15 CrossRef
  35. Gao J, Zhang H, Arbman G et al (2008) RAD50/MRE11/NBS1 proteins in relation to tumour development and prognosis in patients with microsatellite stable colorectal cancer. Histol Histopathol 23:1495-502
  36. Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102:464-74 CrossRef
  37. Cheng Z, Wang W, Song YN et al (2012) hOGG1, p53 genes, and smoking interactions are associated with the development of lung cancer. Asian Pac J Cancer Prev 13:1803-808 CrossRef
  38. Peng WJ, He Q, Yang JX et al (2012) Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep 39:5187-194 CrossRef
  39. Zhang Y, Chen GQ, Ji Y et al (2012) Quantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep 39:6203-211 CrossRef
  
• 作者单位：Lixin Wang (1)
  Jinsong Cheng (2)
  Jinyu Gao (3)
  Jipeng Wang (1)
  Xiaoning Liu (4)
  Liwen Xiong (5)
  
  1. Department of Respiratory Medicine, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China
  2. Department of Medical Oncology, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China
  3. Department of Gynecology and Obstetrics, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China
  4. Central Laboratory, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China
  5. Department of Pulmonary Diseases, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200030, People’s Republic of China
  
• ISSN：1573-4978

文摘

Nijmegen Breakage Syndrome protein 1 (NBS1) is one of the most important DNA repair proteins playing important roles in maintaining the genomic stability of NDA. Previous studies regarding the association between NBS1 8360G>C (Glu185Gln) polymorphism and lung cancer reported conflicting results. To derive a more precise estimation of this association, a systemic review and meta-analysis was performed. We performed a meta-analysis using eligible case–control studies to summarize the data on the association between the NBS1 Glu185Gln polymorphism and lung cancer risk. Odds ratios (ORs) with corresponding 95?% confidence intervals (95?%CIs) were pooled to assess the association between NBS1 Glu185Gln polymorphism and lung cancer risk. Six case–control studies with a total of 2,348 lung cancer cases and 2,401 controls without canner were included into the meta-analysis. Overall, there was an association between NBS1 Glu185Gln polymorphism and lung cancer risk under the dominant comparison model (fixed-effects OR GluGln/GlnGln vs. GluGlu ?=?1.21, 95?% CI 1.07-.37, P?=?0.002, I 2?=?8.1?%). Subgroup analysis by race suggested a significant association between NBS1 Glu185Gln polymorphism and lung cancer risk in Asians (fixed-effects OR GluGlnGlnGln vs. GluGlu ?=?1.22, 95?% CI 1.06-.41, P?=?0.005) but not in Caucasians (fixed-effects OR GluGlnGlnGln vs. GluGlu ?=?1.17, 95?% CI 0.91-.50, P?=?0.220). This meta-analysis supports that there is an association between NBS1 Glu185Gln polymorphism and lung cancer risk. More studies are needed to further verify this association.